Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: donpat who wrote (10064)	4/16/2018 2:09:23 PM
From: BoredMember	1 Recommendation Recommended By Another_Voice_2 Read Replies (1) \| Respond to of 12873

This is ridiculous. They will easily be able to raise money once their results are announced. In case you missed it, they have already completed initial non-GLP toxicology. And not that it will come to this, but if they wanted to "cleanup the Allexcel-Theracour-Nanoviricide IP jumble" as you call it, they wouldn't be looking to raise more money. They would just wait until Nanoviricides was unable to make payment to Theracour and all rights would revert to them. It isn't a jumble. It was set up like this to protect us and the company from a hostile take over, which hasn't happened, so apparently it was a good plan. Once the new CEO is in place, and they announce they have completed their IND FDA requirements, the money will come flowing in. All you naysayers will be left with your mouths open as we laugh on the beach.